UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2012-01, Vol.35 (1), p.15-36

2012

Volltextzugriff (PDF)

Long‐term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience

Alimentary pharmacology & therapeutics, 2018-03, Vol.47 (5), p.588-595

2018

Volltextzugriff (PDF)

Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study

Alimentary Pharmacology & Therapeutics (Suppl), 2018-04, Vol.47 (7), p.906-912

2018

Volltextzugriff (PDF)

Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab

Gut, 2018-02, Vol.67 (2), p.237-243

2018

Volltextzugriff (PDF)

Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab

Alimentary pharmacology & therapeutics, 2017-01, Vol.45 (2), p.276-282

2017

Volltextzugriff (PDF)

The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2014-04, Vol.39 (7), p.712-720

2014

Volltextzugriff (PDF)

Systematic review: New serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes

Autoimmunity reviews, 2015-03, Vol.14 (3), p.231-245

2015

Volltextzugriff (PDF)

Fetal death in utero and miscarriage in a patient with Crohn's disease under therapy with ustekinumab: case-report and review of the literature

BMC gastroenterology, 2017-06, Vol.17 (1), p.80-80, Article 80

2017

Volltextzugriff (PDF)

Undetectable anti‐TNF drug levels in patients with long‐term remission predict successful drug withdrawal

Alimentary pharmacology & therapeutics, 2015-08, Vol.42 (3), p.356-364

2015

Volltextzugriff (PDF)

Letter: stool adalimumab detection in ulcerative colitis and Crohn's disease

Alimentary pharmacology & therapeutics, 2015-07, Vol.42 (2), p.240-240

2015

Volltextzugriff (PDF)

Impact of mucosal healing on long‐term outcomes in ulcerative colitis treated with infliximab: a multicenter experience

Alimentary Pharmacology & Therapeutics (Suppl), 2013-05, Vol.37 (10), p.998-1004

2013

Volltextzugriff (PDF)

Combination of C-reactive Protein, Infliximab Trough Levels, and Stable but Not Transient Antibodies to Infliximab Are Associated With Loss of Response to Infliximab in Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2015-07, Vol.9 (7), p.525-531

2015

Volltextzugriff (PDF)

Letter: thiopurines ‐ is less really more? Authors’ reply

Alimentary pharmacology & therapeutics, 2018-01, Vol.47 (1), p.150-150

2018

Volltextzugriff (PDF)

Letter: new thresholds need to be defined when using point of care assays to monitor infliximab trough levels in IBD patients

Alimentary pharmacology & therapeutics, 2018-06, Vol.47 (11), p.1571-1573

2018

Volltextzugriff (PDF)

Letter: infliximab de‐escalation based on trough levels in patients with inflammatory bowel disease

Alimentary Pharmacology & Therapeutics (Suppl), 2015-10, Vol.42 (7), p.939-940

2015

Volltextzugriff (PDF)

Response to Bodini et al

The American journal of gastroenterology, 2015-03, Vol.110 (3), p.473-473

2015

Volltextzugriff (PDF)

The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region

Annals of the rheumatic diseases, 2015-08, Vol.74 (8), p.e40-e40

2015

Volltextzugriff (PDF)

Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases

Alimentary Pharmacology & Therapeutics (Suppl), 2013-10, Vol.38 (8), p.914-924

2013

Volltextzugriff (PDF)

Response to Zidar and Tepes

The American journal of gastroenterology, 2017-03, Vol.112 (3), p.515-515

2017

Volltextzugriff (PDF)

Management of perianal fistulas in Crohn’s disease: a 2021 update of the French National Society of Coloproctology consensus

Techniques in coloproctology, 2022-10, Vol.26 (10), p.805-811

2022

Volltextzugriff (PDF)

Predictive Models of Therapeutic Response to Vedolizumab: A Novel Step into Personalized Medicine in Crohn's Disease?

Inflammatory bowel diseases, 2018-05, Vol.24 (6), p.1193-1195

2018

Volltextzugriff (PDF)

Intestinal Conventional Ultrasonography, Contrast-Enhanced Ultrasonography and Magnetic Resonance Enterography in Assessment of Crohn’s Disease Activity: A Comparison with Surgical Histopathology Analysis

Digestive diseases and sciences, 2022-06, Vol.67 (6), p.2492-2502

2022

Volltextzugriff (PDF)

Factors associated with pregnancy outcome in anti‐TNF treated women with inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2014-08, Vol.40 (4), p.363-373

2014

Volltextzugriff (PDF)

Kinetics of Antibodies Against Adalimumab Are Not Associated With Poor Outcomes in IBD

The American journal of gastroenterology, 2015-05, Vol.110 (5), p.777-778

2015

Volltextzugriff (PDF)

Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors’ reply

Alimentary pharmacology & therapeutics, 2017-03, Vol.45 (5), p.760-762

2017

Volltextzugriff (PDF)

1 – 25 von 276

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(241)
Mit Volltextzugriff
(249)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(72)
Science & Technology
(72)
Life Sciences & Biomedicine
(65)
Gastroenterology & Hepatology
(53)
Female
(39)
Male
(39)
Life Sciences
(37)
Adult
(34)
Middle Aged
(27)
Pharmacology & Pharmacy
(27)
Colitis, Ulcerative - Drug Therapy
(16)
Treatment Outcome
(15)
Biological And Medical Sciences
(14)
Medical Sciences
(14)
Infliximab
(13)
Aged
(12)
Gastroenterology. Liver. Pancreas. Abdomen
(12)
Sciences Biologiques Et Medicales
(12)
Sciences Medicales
(12)
Pharmacology. Drug Treatments
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease

Long‐term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience

Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study

Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab

Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab

The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease

Systematic review: New serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes

Fetal death in utero and miscarriage in a patient with Crohn's disease under therapy with ustekinumab: case-report and review of the literature

Undetectable anti‐TNF drug levels in patients with long‐term remission predict successful drug withdrawal

Letter: stool adalimumab detection in ulcerative colitis and Crohn's disease

Impact of mucosal healing on long‐term outcomes in ulcerative colitis treated with infliximab: a multicenter experience

Combination of C-reactive Protein, Infliximab Trough Levels, and Stable but Not Transient Antibodies to Infliximab Are Associated With Loss of Response to Infliximab in Inflammatory Bowel Disease

Letter: thiopurines ‐ is less really more? Authors’ reply

Letter: new thresholds need to be defined when using point of care assays to monitor infliximab trough levels in IBD patients

Letter: infliximab de‐escalation based on trough levels in patients with inflammatory bowel disease

Response to Bodini et al

The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region

Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases

Response to Zidar and Tepes

Management of perianal fistulas in Crohn’s disease: a 2021 update of the French National Society of Coloproctology consensus

Predictive Models of Therapeutic Response to Vedolizumab: A Novel Step into Personalized Medicine in Crohn's Disease?

Intestinal Conventional Ultrasonography, Contrast-Enhanced Ultrasonography and Magnetic Resonance Enterography in Assessment of Crohn’s Disease Activity: A Comparison with Surgical Histopathology Analysis

Factors associated with pregnancy outcome in anti‐TNF treated women with inflammatory bowel disease

Kinetics of Antibodies Against Adalimumab Are Not Associated With Poor Outcomes in IBD

Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors’ reply

Suchergebnisse filtern